JBIO
HEALTHCAREJade Biosciences, Inc.
AI Insight
What's Moving JBIO Today?
No stock-specific AI insight has been generated for JBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.67$28.00
$22.25
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-2.63
Dividend Yield—
Dividend / Share—
ROE-89.2%
Profit Margin—
Debt / Equity—
Trading
Volume543K
Avg Volume (10D)—
Shares Outstanding60.9M
JBIO News
20 articles- Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·Jun 5, 2026
- Jade Biosciences Announces Pricing of Public Offering of Common StockYahoo Finance·Jun 4, 2026
- Jade Biosciences Announces Proposed Underwritten Public OfferingYahoo Finance·Jun 3, 2026
- Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsMarketbeat·Jun 2, 2026
- Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA NephropathyYahoo Finance·Jun 1, 2026
- Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA NephropathyYahoo Finance·May 29, 2026
- Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term GainsYahoo Finance·May 29, 2026
- Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal AntibodyYahoo Finance·May 26, 2026
- Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA NephropathyYahoo Finance·May 26, 2026
- Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 23, 2026
- Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical OfficerYahoo Finance·Apr 22, 2026
- Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In GrowthYahoo Finance·Mar 28, 2026
- Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 6, 2026
- Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout NearsMarketbeat·Feb 28, 2026
- Jade Biosciences to Participate in Upcoming ConferencesYahoo Finance·Feb 11, 2026
- H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak RevenueYahoo Finance·Jan 19, 2026
- Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last weekYahoo Finance·Jan 6, 2026
- Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Jade Biosciences Announces $45 Million Private PlacementYahoo Finance·Dec 15, 2025
All 20 articles loaded
Price Data
Open$22.18
Previous Close$21.97
Day High$23.49
Day Low$21.97
52 Week High$28.00
52 Week Low$6.67
52-Week Range
$6.67$28.00
$22.25
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-2.63
Dividend Yield—
Dividend / Share—
ROE-89.2%
Profit Margin—
Debt / Equity—
Trading
Volume543K
Avg Volume (10D)—
Shares Outstanding60.9M
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—